Poland· PL-100461434

Xerava

A eravacycline product containing eravacyclinum, registered in Poland by PAION Pharma GmbH. The same ATC class is registered in 11 of our 19 countries.

ATC J01AA13

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedXeravaATCJ01AA13REGISTER NO.PL-100461434PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Eravacycline is registered in 11 of 19 countries.

Countries holding a registration under ATC J01AA13 (eravacycline), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose

Eravacycline · ATC J01AA13

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Eravacyclinum
Manufacturer
PAION Pharma GmbH
Country
Poland (PL)
ATC code
J01AA13
ATC class
Eravacycline
Defined daily dose
0.14 g, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    04260727580322

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

31 interactions on record for eravacycline.

Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Eravacycline · interactions on record

31 records

  • 11 severe
  • 11 moderate
  • 9 minor

Most severe, free to view

  • AcitretinD05BB02severe
  • IsotretinoinD10AD04severe
  • IsotretinoinD10BA01severe
  • Aminolevulinic acidL01XD04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Eravacycline in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All eravacycline products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Xerava
  • Liechtenstein · Xerava
  • Norway · Xerava

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2b99194c-b314-4932-bbe6-bc4563d6dae3
GET /v1/drugs/2b99194c-b314-4932-bbe6-bc4563d6dae3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania koncentratu roztworu do infuzji",
  "source": "urpl",
  "strength": "100 mg",
  "packaging": "Rp ¦ EU/1/18/1312/004 ¦ 142779\n12 fiol. 100 mg proszku\nRp ¦ EU/1/18/1312/003 ¦ 142780\n1 fiol. 100 mg proszku\n04260727580322 ¦ Rp ¦ EU/1/18/1312/005 ¦ 142781\n10 fiol. 100 mg proszku",
  "substance": "Eravacyclinum 100 mg",
  "common_name": "Eravacyclinum",
  "pl_product_id": "100461434",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about eravacycline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.